Share Name Share Symbol Market Type Share ISIN Share Description
Salvarx Group Plc LSE:SALV London Ordinary Share IM00BZ4SS228 ORD 2.5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 4.50 0.00 00:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 0.0 -0.5 1.0 4.5 2

SalvaRx Group plc Cancellation of AIM listing /Potential acquisition

20/12/2019 10:30am

UK Regulatory (RNS & others)

Salvarx (LSE:SALV)
Historical Stock Chart

From Jan 2019 to Jan 2021

Click Here for more Salvarx Charts.


RNS Number : 6523X

SalvaRx Group plc

20 December 2019

20 December 2019

SalvaRx Group plc

("SalvaRx" or the "Company")

Cancellation of trading on AIM / Potential acquisition

SalvaRx provides the following information regarding the admission of the Company's ordinary shares ("Ordinary Shares") to trading on AIM.

As previously announced, following the suspension of the Company's Ordinary Shares from trading on AIM on 9 July 2019 ("Suspension"), if neither a reverse takeover nor re-admission to trading on AIM as an investing company under the AIM Rules are completed within six months of the date of Suspension, then the Ordinary Shares will be cancelled from trading on AIM pursuant to AIM Rule 41.

As noted in the Company's interim results for the six months ended 30 June 2019, the Company has been evaluating a number of potential acquisition opportunities. The Company is now pleased to announce that it is in advanced discussions with an acquisition target which is a leader in the field of oral immune therapies. Should this proposed acquisition proceed, the Board of SalvaRx anticipates making a further announcement early in the new year, setting out full details of the transaction.

Despite efforts to conclude a reverse takeover before the cancellation date, it will not be possible to conclude the proposed transaction before 10 January 2020. On this basis, the cancellation of the admission to trading of the Ordinary Shares on AIM is expected to take effect from 7.00 a.m. on 10 January 2020.


 SalvaRx Group plc                             Tel: +44 (0) 01624 
  Denham Eke                                         639396 
 SP Angel Corporate Finance LLP                 Tel: +44 (0) 20 
  Nominated Adviser and Broker                      3470 0470 
  Matthew Johnson / Caroline Rowe (Corporate 
  Abigail Wayne (Corporate Broking) 
 Peterhouse Corporate Finance Limited             Tel: +44 (0) 20 
  Joint Broker                                          7469 0932 
  Lucy Williams / Duncan Vasey 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

December 20, 2019 05:30 ET (10:30 GMT)

1 Year Salvarx Chart

1 Year Salvarx Chart

1 Month Salvarx Chart

1 Month Salvarx Chart
ADVFN Advertorial
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20210126 19:07:11